vs
EPLUS INC（PLUS）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是EPLUS INC的1.0倍（$622.0M vs $614.8M），Royalty Pharma plc净利率更高（34.4% vs 5.7%，领先28.7%），EPLUS INC同比增速更快（20.3% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 2.3%）
ePlus Inc.是美国的科技咨询解决方案提供商，业务覆盖网络安全、云计算、网络架构、协作办公、人工智能及前沿技术领域，为超5000家客户提供定制化解决方案、专业咨询与托管服务，助力企业实现数字化转型与技术升级。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
PLUS vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.0倍
$614.8M
营收增速更快
PLUS
高出15.5%
4.8%
净利率更高
RPRX
高出28.7%
5.7%
两年增速更快
RPRX
近两年复合增速
2.3%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $614.8M | $622.0M |
| 净利润 | $35.1M | $214.2M |
| 毛利率 | 25.8% | — |
| 营业利润率 | 7.1% | 62.4% |
| 净利率 | 5.7% | 34.4% |
| 营收同比 | 20.3% | 4.8% |
| 净利润同比 | 45.2% | 2.9% |
| 每股收益（稀释后） | $1.33 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLUSRPRX
| Q4 25 | $614.8M | $622.0M | ||
| Q3 25 | $608.8M | $609.3M | ||
| Q2 25 | $637.3M | $578.7M | ||
| Q1 25 | — | $568.2M | ||
| Q4 24 | $493.2M | $593.6M | ||
| Q3 24 | $493.4M | $564.7M | ||
| Q2 24 | $535.7M | $537.3M | ||
| Q1 24 | — | $568.0M |
净利润PLUSRPRX
| Q4 25 | $35.1M | $214.2M | ||
| Q3 25 | $34.9M | $288.2M | ||
| Q2 25 | $37.7M | $30.2M | ||
| Q1 25 | — | $238.3M | ||
| Q4 24 | $24.1M | $208.2M | ||
| Q3 24 | $31.3M | $544.0M | ||
| Q2 24 | $27.3M | $102.0M | ||
| Q1 24 | — | $4.8M |
毛利率PLUSRPRX
| Q4 25 | 25.8% | — | ||
| Q3 25 | 26.6% | — | ||
| Q2 25 | 23.3% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 25.4% | — | ||
| Q3 24 | 25.8% | — | ||
| Q2 24 | 23.7% | — | ||
| Q1 24 | — | — |
营业利润率PLUSRPRX
| Q4 25 | 7.1% | 62.4% | ||
| Q3 25 | 8.0% | 70.1% | ||
| Q2 25 | 5.7% | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | 3.3% | 60.9% | ||
| Q3 24 | 5.5% | — | ||
| Q2 24 | 5.9% | 50.2% | ||
| Q1 24 | — | -13.0% |
净利率PLUSRPRX
| Q4 25 | 5.7% | 34.4% | ||
| Q3 25 | 5.7% | 47.3% | ||
| Q2 25 | 5.9% | 5.2% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | 4.9% | 35.1% | ||
| Q3 24 | 6.3% | 96.3% | ||
| Q2 24 | 5.1% | 19.0% | ||
| Q1 24 | — | 0.8% |
每股收益（稀释后）PLUSRPRX
| Q4 25 | $1.33 | $0.49 | ||
| Q3 25 | $1.32 | $0.67 | ||
| Q2 25 | $1.43 | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | $0.91 | $0.46 | ||
| Q3 24 | $1.17 | $1.21 | ||
| Q2 24 | $1.02 | $0.23 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $326.3M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.1B | $9.7B |
| 总资产 | $1.8B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资PLUSRPRX
| Q4 25 | $326.3M | $618.7M | ||
| Q3 25 | $402.2M | $938.9M | ||
| Q2 25 | $480.2M | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $253.1M | $929.0M | ||
| Q3 24 | $187.5M | $950.1M | ||
| Q2 24 | $349.9M | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务PLUSRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益PLUSRPRX
| Q4 25 | $1.1B | $9.7B | ||
| Q3 25 | $1.0B | $9.6B | ||
| Q2 25 | $1.0B | $9.5B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | $962.3M | $10.3B | ||
| Q3 24 | $947.0M | $10.3B | ||
| Q2 24 | $921.9M | $9.8B | ||
| Q1 24 | — | $9.9B |
总资产PLUSRPRX
| Q4 25 | $1.8B | $19.6B | ||
| Q3 25 | $1.8B | $19.3B | ||
| Q2 25 | $1.8B | $18.3B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | $1.8B | $18.2B | ||
| Q3 24 | $1.7B | $18.0B | ||
| Q2 24 | $1.7B | $17.7B | ||
| Q1 24 | — | $16.1B |
负债/权益比PLUSRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-87.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | -2.49× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PLUSRPRX
| Q4 25 | $-87.4M | $827.1M | ||
| Q3 25 | $-34.8M | $702.6M | ||
| Q2 25 | $-99.0M | $364.0M | ||
| Q1 25 | — | $596.1M | ||
| Q4 24 | $65.7M | $742.5M | ||
| Q3 24 | $-21.6M | $703.6M | ||
| Q2 24 | $97.1M | $658.2M | ||
| Q1 24 | — | $664.6M |
现金转化率PLUSRPRX
| Q4 25 | -2.49× | 3.86× | ||
| Q3 25 | -1.00× | 2.44× | ||
| Q2 25 | -2.63× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 2.72× | 3.57× | ||
| Q3 24 | -0.69× | 1.29× | ||
| Q2 24 | 3.55× | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLUS
| All Others Customer End Market | $107.0M | 17% |
| Technology Customer End Market | $89.4M | 15% |
| Health Care Customer End Market | $81.5M | 13% |
| Financial Services Customer End Market | $66.1M | 11% |
| Professional Services Reporting Unit | $64.1M | 10% |
| Security | $61.1M | 10% |
| State And Local Government And Educational Institutions | $59.9M | 10% |
| Managed Services Reporting Unit | $48.8M | 8% |
| Other Product | $21.1M | 3% |
| Collaboration | $13.4M | 2% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
